Kyowa Kirin

Prostrakan, a specialized Scottish-based pharmaceutical company, was renamed to Kyowa Kirin in April 18, 2016.
Prostrakan was acquired by Kyowa Hakko Kirin Co. Ltd. (KHK) based in Tokyo in 2011, and the Japanese company decided that, in order to present a consistent image worldwide, all its Western subsidiaries of Pharmaceutical companies would be harmonized with the name of Kyowa Kirin. Prostrakan, based in Galashiels, will trade as Kyowa Kirin International plc while the subsidiaries in different countries shall adopt the name of Kyowa Kirin in the local names of their companies.

Apart from the change in name, this move will have no impact on the business activity that takes place in Europe and the United States of America.
Our new website may be found here Kyowa-Kirin website


Belgian SMB is an innovative pharmaceutical company with international horizons. Its aim is to grow into a leading European force in the field of oral or lung delivery
systems for medicines.
For more than 50 years, SMB has been utilizing its expertise and know-how as well as the latest technological advances to identify and develop drug delivery
systems specifically designed for selected active ingredients to improve patient outcomes regarding the following:

Efficacy (enhancing bioavailability, solubility, etc.)
Safety by using lower strengths with the same efficacy
Patient tolerability and compliance

SMB is currently active in more than 40 countries.
Click here to see more in the company’s website.


Who we are
We are a company with extensive experience in medicines of general use, offering a wide portfolio of products and intellectual property to other pharmaceutical
companies. We have a proven record in obtaining regulatory approval before the expiration of patents and we have obtained marketing authorizations in more than 140 countries to date. Our company draws on the development and production capabilities of its parent company, Teva Pharmaceuticals Ltd (NYSE and TASE: TEVA), the Research
& Development specialists which maintain a strong growth plan.

What we do
We provide generic pharmaceuticals for human use, mainly in the form of tablets, capsules and injections.
Our integrated portfolio includes a growing range of specialized products, including oncology, in pharmaceutical forms that include sustained release, oral, solid, semi-solid, suspensions, transdermal, suppositories, creams, ointments, liquids and injectable products.

Our sites
Our company has a local presence in Iceland, Germany, France, Spain, Italy, Poland, Brazil and Australia. We provide services and products to most European nations and we have marketing authorizations in fast growing markets such as Russia, Poland, Latin America and Asia.

Click here to see more in the company’s website.

Intas is a leading, vertically integrated global pharmaceutical company manufacturing and marketing pharmaceuticals.

The success and uninterrupted development of Intas lies in the clinical execution of successful strategic moves that have taken place in the fields of manufacturing, biotechnology and global business for three decades, having presence in the areas of the cardiovascular system (CVS), diabetes, gynecology, infertility, respiratory care, gastroenterology, pain management as well as other therapeutic segments.

Intas is present in more than 70 countries worldwide having strong sales, marketing and distribution infrastructure in markets such as North America, Europe, Central and Latin America, Africa, Australia, New Zealand.

Intas’ global strategy includes alliances with leading global pharmaceuticals companies for product development and distribution as well as for direct product distribution.

Intas has made a substantial commitment for its Biological Business Unit in terms of creating R&D, manufacturing and marketing capabilities for its biotech portfolio. Currently, Intas has commercialized 11 biologic products and continues its R & D in areas of chronic diseases such as oncology (cancer), rheumatology, autoimmunity, nephrology, ophthalmology, and plasma-based therapies.

Intas has made strategic investments in ten manufacturing facilities worldwide. Among these, these facilities have been approved by several major international regulators, including the US Food and Drug Administration (FDA).

Click here to see more in the company’s website.